---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Oral selective estrogen receptor degraders and estrogen receptor degraders"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Oral selective estrogen receptor degraders and estrogen receptor degraders. Topics: Guideline recommendation: NCCN, elacestrant and imlunestrant for ESR1-mutated disease; Guideline recommendation: NCCN, imlunestrant plus abemaciclib and vepdegestrant; Guideline recommendation: ABC8, oral SERD class; Guideline background: ASCO 2021, ESR1 testing before oral SERD approvals; 18 further topics. 22 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/oral-selective-estrogen-receptor-degraders-and-estrogen-receptor-degraders"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Oral selective estrogen receptor degraders and estrogen receptor degraders

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Oral Selective Estrogen Receptor Degraders and Estrogen Receptor Degraders

<a id="topic-2.2.2.1.1-1"></a>

### Guideline recommendation: NCCN, elacestrant and imlunestrant for ESR1-mutated disease

> “After a prior line of AI with or without CDK4/6 inhibitor therapy (in adjuvant or metastatic setting), options for ESR-1 mutated tumors include elacestrant or imlunestrant.”
> “Therefore, the NCCN panel recommends elacestrant as an option after a prior line of AI a with CDK4/6 inhibitor therapy (in adjuvant or metastatic setting) (Figure 5).”
> “The NCCN Panel recommends imlunestrant after a prior line of AI with or without CDK4/6 inhibitor therapy (in adjuvant or metastatic setting) (Figure 5).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.1-2"></a>

### Guideline recommendation: NCCN, imlunestrant plus abemaciclib and vepdegestrant

> “noting that the combination of imlunestrant and abemaciclib may be most effective in those with ESR1 mutations and no prior CDK4/6 inhibitor.”
> “The NCCN panel has included vepdegestrant as an option after a prior line of endocrine therapy in the metastatic setting for patients with ESR1-mutated breast cancer (Figure 5).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.1-3"></a>

### Guideline recommendation: ABC8, oral SERD class

> “Since the approval of elacestrant based on the EMERALD trial [ 33 ], the class of oral SERDs has expanded with new agents now supported by phase 3 evidence. Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.”
> “Camizestrant showed encouraging results in the SERENA-6 trial using a ctDNA-guided switch strategy upon emergence of ESR1 mutations , though the clinical utility of treatment modification without radiological progression remains to be established [ 35 ].”
> “The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.1-4"></a>

### Guideline background: ASCO 2021, ESR1 testing before oral SERD approvals

> “There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. Existing data suggest reduced efficacy of AIs compared with the selective estrogen receptor degrader fulvestrant in patients who have tumor or circulating tumor DNA (ctDNA) with ESR1 mutations (type: informal consensus; evidence quality: insufficient; strength of recommendation: moderate).”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.1-5"></a>

### Comparator regulatory information: elacestrant

> “ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test”
> “with disease progression following at least one line of endocrine therapy.”
> “The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.2.2.1.1-6"></a>

### Elacestrant, EMERALD: trial population and comparator

> “Patients were required to have disease progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.”
> “investigator’s choice of endocrine therapy (n=239), which included fulvestrant (n=166), or an aromatase inhibitor (n=73; anastrozole, letrozole or exemestane).”
> “An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### Elacestrant, EMERALD: progression-free survival

> “PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).”
> “Similarly, 12-month PFS rates were 22.3% (95% CI, 15.2 to 29.4) versus 9.4% (95% CI, 4.0 to 14.8), respectively, in all patients versus 26.8% (95% CI, 16.2 to 37.4) and 8.2% (95% CI, 1.3 to 15.1), respectively, in patients with ESR1 mutation.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.1-8"></a>

### Elacestrant, EMERALD: FDA review of the ESR1-mutated subgroup

> “The median PFS was 3.8 months (95% CI, 2.2 to 7.3) in the elacestrant arm and 1.9 months (95% CI, 1.9 to 2.1) in the SOC arm.”
> “By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.1.1-9"></a>

### Elacestrant, EMERALD: duration of prior CDK4/6 inhibitor therapy

> “In patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63).”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.1.1-10"></a>

### Elacestrant, EMERALD: safety

> “Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.1-11"></a>

### Comparator regulatory information: imlunestrant

> “as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy”
> “in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.2.2.1.1-12"></a>

### Imlunestrant, EMBER-3: FDA approval of monotherapy

> “In the ESR1 mutated population (n=256), a statistically significant difference in investigator-assessed PFS for imlunestrant compared to investigator’s choice of endocrine therapy was observed. The median PFS was 5.5 months (95% CI: 3.9, 7.4) in the imlunestrant arm and 3.8 months (95% CI: 3.7, 5.5) in the investigator's choice arm (hazard ratio 0.62 [95% CI: 0.46, 0.82]; p-value 0.0008).”

Source: [FDA imlunestrant approval notice (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)

<a id="topic-2.2.2.1.1-13"></a>

### Imlunestrant, EMBER-3: primary results

> “Overall, 874 patients underwent randomization, with 331 assigned to imlunestrant, 330 to standard therapy, and 213 to imlunestrant–abemaciclib.”
> “In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).”
> “The incidence of grade 3 or higher adverse events was 17.1% with imlunestrant, 20.7% with standard therapy, and 48.6% with imlunestrant–abemaciclib.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.1-14"></a>

### Imlunestrant, EMBER-3: updated overall survival

> “In patients with ESR1 m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].”

Source: [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)

<a id="topic-2.2.2.1.1-15"></a>

### Comparator regulatory information: vepdegestrant

> “VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.”

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.1-16"></a>

### Vepdegestrant, VERITAC-2: FDA approval

> “On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader”
> “Patients were required to have disease progression on one to two lines of endocrine therapy, including one line with a CDK4/6 inhibitor.”
> “Median PFS was 5 months (95% CI: 3.7, 7.4) in the vepdegestrant arm and 2.1 months (95% CI: 1.9, 3.5) in the fulvestrant arm (hazard ratio 0.57 [95% CI: 0.42, 0.77]; p-value 0.0001). ORR was 19% (95% CI: 12, 27) and 4% (95% CI: 1.6, 10) in the respective arms.”
> “The recommended vepdegestrant dose is 200 mg taken orally once daily with food until disease progression or unacceptable toxicity.”

Source: [FDA vepdegestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)

<a id="topic-2.2.2.1.1-17"></a>

### Vepdegestrant, VERITAC-2: primary results

> “Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).”
> “Adverse events of grade 3 or higher occurred in 23.4% of the patients in the vepdegestrant group and in 17.6% of the patients in the fulvestrant group. Adverse events led to treatment discontinuation in 2.9% and 0.7% of the patients, respectively.”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.1.1-18"></a>

### Comparator regulatory information: camizestrant

> “ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test”
> “This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation.”

Source: [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.1-19"></a>

### Camizestrant, SERENA-6: first-line switch at ESR1 mutation detection

> “All patients were required to be currently receiving treatment of an AI in combination with a CDK4/6 inhibitor for ≥ 6 months as the initial endocrine based treatment with no evidence of disease progression as per investigator assessment.”
> “Median PFS was 16 months (95% CI: 12.7, 18.2) in the camizestrant and CDK4/6 inhibitor arm and 9.2 months (95% CI: 7.2, 9.5) in the AI and CDK4/6 inhibitor arm (Hazard ratio 0.44 [95% CI: 0.31, 0.60]; p-value < 0.00001). At the time of the PFS analysis, OS data were not mature.”

Source: [FDA camizestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative)

<a id="topic-2.2.2.1.1-20"></a>

### Camizestrant, SERENA-4: first-line trial in unselected patients

> “The SERENA-4 Phase III trial of AstraZeneca’s Etcamah (camizestrant) in combination with palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, did not meet the primary endpoint of progression-free survival (PFS), however a numerical improvement was observed in the upfront 1st-line treatment of patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer who have not received any systemic treatment for advanced disease.”

Source: [AstraZeneca SERENA-4 update announcement (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/update-serena-4-phase-iii-trial.html)

<a id="topic-2.2.2.1.1-21"></a>

### Giredestrant plus everolimus, evERA: primary results

> “Patients were randomized 1:1 to giredestrant plus everolimus (giredestrant-everolimus) or standard endocrine therapy (i.e., exemestane, fulvestrant, or tamoxifen) plus everolimus (standard endocrine therapy-everolimus).”
> “median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).”
> “The most common adverse events in both groups were stomatitis (47.3% and 48.9%, respectively), diarrhea (26.9% and 22.6%), and anemia (23.6% and 21.0%).”

Source: [Mayer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674676/)

<a id="topic-2.2.2.1.1-22"></a>

### Giredestrant plus everolimus: regulatory status

> “the United States (U.S.) Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence or progression on a prior endocrine-based regimen. The FDA is expected to make a decision on the approval by 18 December 2026.”

Source: [Roche giredestrant New Drug Application acceptance announcement (2026)](https://www.roche.com/media/releases/med-cor-2026-02-20)

Additional sources: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext); [Bidard et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454637/); [Oliveira et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39481395/); [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
